Literature DB >> 33432346

Neoadjuvant Immunotherapy: An Evolving Paradigm Shift?

Marijo Bilusic1, James L Gulley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33432346      PMCID： PMC8246798          DOI： 10.1093/jnci/djaa217

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  19 in total

Review 1.  Neoadjuvant checkpoint blockade for cancer immunotherapy.

Authors:  Suzanne L Topalian; Janis M Taube; Drew M Pardoll
Journal:  Science       Date:  2020-01-31       Impact factor: 47.728

Review 2.  Advances in PET Detection of the Antitumor T Cell Response.

Authors:  M N McCracken; R Tavaré; O N Witte; A M Wu
Journal:  Adv Immunol       Date:  2016-04-05       Impact factor: 3.543

3.  Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.

Authors:  Alberto Briganti; Giorgio Gandaglia; Simone Scuderi; Andrea Gallina; Renzo Colombo; Nicola Fossati; Francesco Barletta; Antony Pellegrino; Luigi Nocera; Francesco Montorsi; Andrea Necchi
Journal:  Eur Urol       Date:  2020-01-03       Impact factor: 20.096

4.  Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.

Authors:  Rita Nanda; Minetta C Liu; Christina Yau; Rebecca Shatsky; Lajos Pusztai; Anne Wallace; A Jo Chien; Andres Forero-Torres; Erin Ellis; Heather Han; Amy Clark; Kathy Albain; Judy C Boughey; Nora T Jaskowiak; Anthony Elias; Claudine Isaacs; Kathleen Kemmer; Teresa Helsten; Melanie Majure; Erica Stringer-Reasor; Catherine Parker; Marie C Lee; Tufia Haddad; Ronald N Cohen; Smita Asare; Amy Wilson; Gillian L Hirst; Ruby Singhrao; Katherine Steeg; Adam Asare; Jeffrey B Matthews; Scott Berry; Ashish Sanil; Richard Schwab; W Fraser Symmans; Laura van 't Veer; Douglas Yee; Angela DeMichele; Nola M Hylton; Michelle Melisko; Jane Perlmutter; Hope S Rugo; Donald A Berry; Laura J Esserman
Journal:  JAMA Oncol       Date:  2020-05-01       Impact factor: 31.777

5.  Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

Authors:  Romain Banchereau; Daniel Castellano; Thomas Powles; Mark Kockx; Alejo Rodriguez-Vida; Ignacio Duran; Simon J Crabb; Michiel S Van Der Heijden; Bernadett Szabados; Albert Font Pous; Gwenaelle Gravis; Urbano Anido Herranz; Andrew Protheroe; Alain Ravaud; Denis Maillet; Maria Jose Mendez; Cristina Suarez; Mark Linch; Aaron Prendergast; Pieter-Jan van Dam; Diana Stanoeva; Sofie Daelemans; Sanjeev Mariathasan; Joy S Tea; Kelly Mousa
Journal:  Nat Med       Date:  2019-11-04       Impact factor: 53.440

Review 6.  Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy.

Authors:  Jose Carlos Benitez; Jordi Remon; Benjamin Besse
Journal:  Clin Cancer Res       Date:  2020-05-20       Impact factor: 12.531

7.  Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Authors:  Valsamo Anagnostou; Patrick M Forde; James R White; Noushin Niknafs; Carolyn Hruban; Jarushka Naidoo; Kristen Marrone; I K Ashok Sivakumar; Daniel C Bruhm; Samuel Rosner; Jillian Phallen; Alessandro Leal; Vilmos Adleff; Kellie N Smith; Tricia R Cottrell; Lamia Rhymee; Doreen N Palsgrove; Christine L Hann; Benjamin Levy; Josephine Feliciano; Christos Georgiades; Franco Verde; Peter Illei; Qing Kay Li; Edward Gabrielson; Malcolm V Brock; James M Isbell; Jennifer L Sauter; Janis Taube; Robert B Scharpf; Rachel Karchin; Drew M Pardoll; Jamie E Chaft; Matthew D Hellmann; Julie R Brahmer; Victor E Velculescu
Journal:  Cancer Res       Date:  2018-12-12       Impact factor: 12.701

8.  Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Authors:  Jing Liu; Stephen J Blake; Michelle C R Yong; Heidi Harjunpää; Shin Foong Ngiow; Kazuyoshi Takeda; Arabella Young; Jake S O'Donnell; Stacey Allen; Mark J Smyth; Michele W L Teng
Journal:  Cancer Discov       Date:  2016-09-23       Impact factor: 39.397

Review 9.  Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges.

Authors:  Mithunah Krishnamoorthy; John G Lenehan; Saman Maleki Vareki
Journal:  J Natl Cancer Inst       Date:  2021-07-01       Impact factor: 13.506

10.  Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.

Authors:  Houssein Abdul Sater; Jennifer L Marté; Peter A Pinto; James L Gulley; Renee N Donahue; Beatriz Walter-Rodriguez; Christopher R Heery; Seth M Steinberg; Lisa M Cordes; Guinevere Chun; Fatima Karzai; Marijo Bilusic; Stephanie A Harmon; Ismail Baris Turkbey; Peter L Choyke; Jeffrey Schlom; William L Dahut; Ravi A Madan
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.